With at least one-quarter of bladder cancer patients presenting with deadly muscle-invasive tumors, decisions on staging and treatment are profound – yet must be made swiftly. Urologic cancer surgeon, Sima Porten, MD, offers the latest guidelines and study findings – including genomics research data – to help physicians guide each patient toward an optimal outcome.